CureVac may let contractors make rival vaccines if own shot fails -CEO

By Tilman Blasshofer and Ludwig Burger

FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday.

The German company saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting investor confidence in its ability to take on rival shots.

"At the moment we are of course fully committed to obtain authorisation, the data will show," CureVac CEO Franz-Werner Haas told Reuters TV, referring to a final read-out that is still pending.

"If this capacity is not to be used - we are working with a whole network of outstanding partners - ... these partners would of course be free to make other products if we don't have a product," he said.

CureVac's manufacturing partners include Celonic Group of Switzerland, Novartis NOVN.S , Bayer BAYGn.DE , Fareva, Wacker WCHG.DE and Rentschler Biopharma SE.

However, Haas stressed that CureVac's efforts to develop a new generation of vaccines, a venture where it collaborates with GlaxoSmithKline GSK.L , would take precedence and that he would continue to draw on the external contractors for that drive

Drug supply chain expert Prashant Yadav said that if CureVac's partners were to make different mRNA vaccine, like Pfizer-BioNtech's PFE.N BNTX.O or Moderna's MRNA.O , it would take at least six to eight weeks to retool their facilities.

Yadav suggested that the Pfizer-BioNTech vaccine might be a better candidate, given that BioNTech is in Germany and many of CureVac's manufacturing partners are in Germany and Austria.

CureVac fails in pivotal COVID-19 vaccine trial with 47%

CureVac crashes after COVID-19 vaccine underwhelms BREAKINGVIEWS-CureVac’s pain may not yet have peaked

Reporting by Tilman Blasshofer, Ludwig Burger and Patricia Weiss; Editing by Pravin Char and Richard Chang

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。


本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示: 您的資金存在風險。杠杆商品可能不適合所有客戶。 請詳細閱讀我們的風險聲明